v3.25.2
Note 14 - Related Party Transactions (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 29, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Nov. 06, 2022
Accounts Payable, Current   $ 3,630   $ 3,630   $ 4,130  
Related Party [Member]              
Accounts Payable, Current   200   200   100  
Glytech License Agreement [Member]              
Related Party Transaction, Amounts of Transaction   0 $ 100 0 $ 100    
Glytech License Agreement [Member] | NRX Pharmaceuticals, Inc [Member] | Minimum [Member]              
Investment Owned, Fair Value             $ 50,000
Consultation Agreement with Dr. Jonathan Javitt [Member]              
Related Party Transaction, Amounts of Transaction   300 200 600 400    
Consultation Agreement with Zachary Javitt [Member]              
Related Party Transaction, Amounts of Transaction   100 $ 100 100 $ 100    
Consulting Agreement, Annual Payment $ 600            
Consulting Agreement, Monthly Payment 100            
Consulting Agreement, Performance Bonus, Target Value $ 300            
Accrued Bonuses, Current   $ 200   $ 200   $ 200  
Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) 50,000            
Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member] | Unrestricted Upon New Drug Application Date [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) 25,000            
Consultation Agreement with Zachary Javitt [Member] | Restricted Stock [Member] | Unrestricted Upon New Drug Approval Date [member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) 25,000